C12N 2310/345
Having at least two different backbone modifications
Official title: having at least two different backbone modifications
C12N2310/345 (Having at least two different backbone modifications) appears on 192 US grants and 325 published applications in this corpus.
Search patents in C12N- Granted patents
- 192
- Published applications
- 325
- Assignees
- 103
- Inventors
- 485
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 8 | 0 |
| 2000 | 6 | 0 |
| 2001 | 13 | 3 |
| 2002 | 7 | 9 |
| 2003 | 9 | 18 |
| 2004 | 6 | 17 |
| 2005 | 3 | 14 |
| 2006 | 6 | 10 |
| 2007 | 4 | 11 |
| 2008 | 2 | 2 |
| 2009 | 5 | 7 |
| 2010 | 6 | 4 |
| 2011 | 3 | 5 |
| 2012 | 5 | 4 |
| 2013 | 3 | 3 |
| 2014 | 4 | 9 |
| 2015 | 4 | 7 |
| 2016 | 10 | 11 |
| 2017 | 6 | 10 |
| 2018 | 8 | 13 |
| 2019 | 9 | 12 |
| 2020 | 7 | 12 |
| 2021 | 10 | 31 |
| 2022 | 11 | 24 |
| 2023 | 12 | 26 |
| 2024 | 7 | 30 |
| 2025 | 10 | 20 |
| 2026 | 6 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Processes for the production of oligonucleotides9 Jun 2026US 12,649,939 B2GlaxoSmithKline Intellectual Property Development Limited
- Compounds and methods for modulating PLP112 May 2026US 12,624,356 B2Ionis Pharmaceuticals, Inc.
- Complement Factor B-modulating compositions and methods of use thereof7 Apr 2026US 12,595,477 B2ADARx Pharmaceuticals, Inc.
- Methods and compositions for neuroprotection7 Apr 2026US 12,595,481 B2Disarm Therapeutics, Inc.
- Compositions for modulating Ataxin 2 expression24 Mar 2026US 12,584,128 B2Ionis Pharmaceuticals, Inc.
- Conjugate compositions comprising phosphoryl guanidine linkages and uses thereof27 Aug 2026US 2026/0250683 A1Avidity Biosciences, Inc.
- Oligonucleotides capable of upregulating glucocerebrosidase expression20 Aug 2026US 2026/0242796 A1Hoffmann-La Roche Inc.
- Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency13 Aug 2026US 2026/0234633 A1ProQR Therapeutics II B.V.
- Compounds and Methods for Reducing KCNT1 Expression13 Aug 2026US 2026/0234639 A1Ionis Pharmaceuticals, Inc.
- Muscle targeting complexes and uses thereof for treating dystrophinopathies6 Aug 2026US 2026/0224726 A1Dyne Therapeutics, Inc.
Most cited
By later US patents
- Inverted chimeric and hybrid oligonucleotides309US 5,652,356 AHybridon, Inc. · 1997
- Alteration of cellular behavior by antisense modulation of mRNA processing259US 6,210,892 B1Isis Pharmaceuticals, Inc. · 2001
- Antisense modulation of BCL-X expression218US 6,172,216 B2Isis Pharmaceuticals, Inc. · 2001
- Antisense modulation of bcl-x expression138US 7,148,204 B2Isis Pharmaceuticala, Inc. · 2006
- Potent LNA oligonucleotides for the inhibition of HIF-1A expression120US 7,589,190 B2Enzon Pharmaceuticals, Inc. · 2009